Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Emerging Science-Based Supplement Health Claims Category Proposed

This article was originally published in The Tan Sheet

Executive Summary

Creating a category of dietary supplement health claims that are based upon "emerging science" and carry label disclaimers would allow FDA to satisfy the Pearson court's mandate, a food science expert suggested at an agency meeting April 4.

You may also be interested in...



Pearson Applies To Both Foods, Supplements - GMA Citizen Petition

FDA should immediately apply the Pearson v. Shalala ruling on health claims to both conventional foods and dietary supplements, the Grocery Manufacturers of America asserts in an April 27 citizen petition, urging the agency to immediately withdraw and revise its implementation plan.

Pearson Applies To Both Foods, Supplements - GMA Citizen Petition

FDA should immediately apply the Pearson v. Shalala ruling on health claims to both conventional foods and dietary supplements, the Grocery Manufacturers of America asserts in an April 27 citizen petition, urging the agency to immediately withdraw and revise its implementation plan.

Pearson Applies To Both Foods, Supplements - GMA Citizen Petition

FDA should immediately apply the Pearson v. Shalala ruling on health claims to both conventional foods and dietary supplements, the Grocery Manufacturers of America asserts in an April 27 citizen petition, urging the agency to immediately withdraw and revise its implementation plan.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091058

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel